Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (Cohort 9 of the dose escalation portion of ...
NPM-139 has potential to provide Wegovy ®-level efficacy with once or twice-yearly administration First-in-human Phase 1 study is expected to initiate in the first half of 2026, pending regulatory ...
Following the positive interim results in 5 patients announced earlier this year, a total of 9 patients have been enrolled as planned The study is progressing according ...
Recent CDC data show that that wastewater SARS-CoV-2 detections are high and that LP.8.1 and related strains XFG and NB.1.8.1 ...
Database workload optimization in the cloud becomes a key part of the way the database team operates. Switching from a reactive to a proactive stance is key to making a successful transition to the ...
Soleno Therapeutics faces scrutiny over Vykat safety after a patient death. Click here to find out why I rate SLNO a Hold.
The WHO lowered its assessment from high to medium, based on several factors, including high population immunity and improved ...
Launch timetable is now imminent for developers of a revolutionary system for medication management as they open an initial SAFE investment round and will fund final product development and market ...
SAN DIEGO, CA / ACCESS Newswire / September 9, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company focused on rebalancing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback